ArticleJournal of studies on alcohol and drugs2015
Adoption of injectable naltrexone in U.S. substance use disorder treatment programs.
Article in Journal of studies on alcohol and drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 58 citations in OpenAlex.
- Enhancing Use of Medications for Opioid Use Disorder Through External Coaching.Psychiatric services (Washington, D.C.) · 2023Trial
- The payer's role in addressing the opioid epidemic: It's more than money.Journal of substance abuse treatment · 2019Trial
- A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.The American journal of psychiatry · 2019Trial
- Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.Journal of psychiatry & neuroscience : JPN · 2018Trial
- Expanding access to medications for opioid use disorder in primary care clinics: an evaluation of common implementation strategies and outcomes.Implementation science communications · 2022Article
- Developmental Considerations for the Use of Naltrexone in Children and Adolescents.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021Article
- Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone.Addiction (Abingdon, England) · 2020Article
- A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.Substance abuse treatment, prevention, and policy · 2020Article
- Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.The American journal of drug and alcohol abuse · 2020Article
- The use of off-label medications in substance abuse treatment programs.Substance abuse · 2020Article
- Systematic Analysis of the Service Process and the Legislative and Regulatory Environment for a Pharmacist-Provided Naltrexone Injection Service in Wisconsin.Pharmacy (Basel, Switzerland) · 2019Article
- Developing an opioid use disorder treatment cascade: A review of quality measures.Journal of substance abuse treatment · 2018Review
- Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies.The American journal on addictions · 2018Review
- Promoting Adoption of Medication for Opioid and Alcohol Use Disorders Through System Change.Journal of studies on alcohol and drugs · 2017Article
- Update on Barriers to Pharmacotherapy for Opioid Use Disorders.Current psychiatry reports · 2017Review
- A review of a national training initiative to increase provider use of MAT to address the opioid epidemic.The American journal on addictions · 2016Review
- The Relationship Between Client Characteristics and Wraparound Services in Substance Use Disorder Treatment Centers.Journal of studies on alcohol and drugs · 2016Article
- Provision of onsite HIV Services in Substance Use Disorder Treatment Programs: A Longitudinal Analysis.Journal of substance abuse treatment · 2015Article
- Treatment strategy profiles in substance use disorder treatment programs: A latent class analysis.Drug and alcohol dependence · 2015Article
- National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.American journal of public health · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
objectiveMedication-assisted treatment for substance use disorders (SUDs) is not widely used in treatment programs. The aims of the current study were to document the prevalence of adoption and implementation of extended-release injectable naltrexone, the newest U.S. Food and Drug Administration-approved medication for alcohol use disorder (AUD), in U.S. treatment programs and to examine associations between organizational and patient characteristics and adoption.
methodThe study used interview data from a nationally representative sample of 307 U.S. SUD treatment programs to examine adoption and implementation of injectable naltrexone.
resultsThirteen percent of programs used injectable naltrexone for AUD, and 3% of programs used it for opioid use disorder. Every treatment program that offered injectable naltrexone to its patients used it in conjunction with psychosocial treatment, particularly cognitive behavioral therapy. Multivariate logistic regression results indicated that adoption was positively associated with the provision of wraparound services, the percentage of privately insured patients, and the presence of inpatient detoxification services. For-profit status and offering inpatient services were negatively associated with adoption. Within adopting programs, an average of 4.1% of AUD patients and 7.1% of patients with opioid use disorder were currently receiving the medication, despite clinical directors' reports of positive patient outcomes, particularly for relapsers and for those who had been noncompliant with other medications. Cost was a significant issue for the majority of adopting organizations.
conclusionsThe rate of adoption of injectable naltrexone in U.S. treatment programs remains limited. Researchers should continue to examine patient, organizational, and external characteristics associated with the adoption and implementation of injectable naltrexone over time.
Indexed as
Identifiers
25486403PMC4263776W2052813313What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.